Drugs / Docusate Sodium
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03342157 | Apr → Aug 2018 | gastroparesis | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00571896 | Jan 2008 → Jun 2009 | constipation disorder | Hartford Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01474499 | Sep 2011 → Mar 2012 | constipation disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03800745 | Nov 2018 → May 2020 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07328880 | Apr 2025 → Apr 2026 overdue | — | Tanta University | Recruiting | No outcome recorded |
| — | NCT00902031 | Apr 2006 → Oct 2010 | constipation disorder | University of Alberta | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 2 | NCT04380090 Comparator | Feb → Jul 2020 | constipation disorder | The Cleveland Clinic | Completed | Missed primary |
| Phase 2 | NCT00001337 Background | May 1993 → May 2024 | Burkitt lymphoma, anaplastic large cell lymphoma, mediastinal gray zone lymphoma, primary mediastinal large B-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT06561035 Background | Sep 2024 → Dec 2027 expected | — | Campbell Clinic | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT03523715 Background | Nov 2017 → Jun 2020 | constipation disorder | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02977286 Background | Jan 2017 → Oct 2019 | constipation disorder | Tufts Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01773096 Background | May 2013 → May 2015 | constipation disorder | Shriners Hospitals for Children | Completed | No outcome recorded |
| Phase 4 | NCT00799201 Background | Aug 2007 → Oct 2012 | constipation disorder | CAMC Health System | Terminated | No outcome recorded |
| — | NCT05423249 Background | Aug 2022 → Nov 2024 | disorder of iron metabolism and transport | Stony Brook University | Completed | No outcome recorded |
| — | NCT01044212 Comparator | Nov 2009 → Feb 2011 | intestinal disorder | University of Rochester | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Docusate sodium | “The first study group, arm B, will be prescribed docusate sodium(Colace) 100mg twice daily orally, and will be instructed to begin taking this the evening of surgery through...” NCT03800745 ↗9“Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours” NCT00799201 ↗ “Docusate Sodium + Sennosides” NCT00001337 ↗ |
| Known as | Colace | “The first study group, arm B, will be prescribed docusate sodium(Colace) 100mg twice daily orally, and will be instructed to begin taking this the evening of surgery through...” NCT03800745 ↗1“Both groups will receive oral docusate sodium (Colace) 100mg twice daily as needed to decrease the risk of constipation.” NCT05423249 ↗ |
| Known as | Docusate | “8. Senokot-S (Sennosides and Docusate) as needed for constipation.” NCT06561035 ↗ |
| Route | Oral | “Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.” NCT00902031 ↗ |